The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
APPLIED GENETIC TECHNOL CORP | COM | 03820J100 | 13,579 | 1,452,216 | SH | SOLE | 1,452,216 | 0 | 0 | ||
CIDARA THERAPEUTICS INC | COM | 171757107 | 14,111 | 1,356,813 | SH | SOLE | 1,356,813 | 0 | 0 | ||
EIGER BIOPHARMACEUTICALS INC | COM | 28249U105 | 18,635 | 1,599,592 | SH | SOLE | 1,599,592 | 0 | 0 | ||
GLAUKOS CORP | COM | 377322102 | 34,930 | 1,018,362 | SH | SOLE | 1,018,362 | 0 | 0 | ||
INVUITY INC | COM | 46187J205 | 6,212 | 1,080,272 | SH | SOLE | 1,080,272 | 0 | 0 | ||
KALVISTA PHARMACEUTICALS INC | COM | 483497103 | 2,333 | 329,942 | SH | SOLE | 329,942 | 0 | 0 | ||
MACROGENICS INC | COM | 556099109 | 21,959 | 1,074,316 | SH | SOLE | 1,074,316 | 0 | 0 | ||
MEI PHARMA INC | COM | 55279B202 | 836 | 580,401 | SH | SOLE | 580,401 | 0 | 0 | ||
OBALON THERAPEUTICS INC | COM | 67424L100 | 21,712 | 2,453,338 | SH | SOLE | 2,453,338 | 0 | 0 | ||
OCERA THERAPEUTICS INC | COM | 67552A108 | 2,621 | 1,248,064 | SH | SOLE | 1,248,064 | 0 | 0 | ||
PARATEK PHARMACEUTICALS INC | COM | 699374302 | 7,890 | 512,366 | SH | SOLE | 512,366 | 0 | 0 | ||
REATA PHARMACEUTICALS INC | CL A | 75615P103 | 285 | 13,058 | SH | SOLE | 13,058 | 0 | 0 | ||
TESARO INC | COM | 881569107 | 271,838 | 2,021,403 | SH | SOLE | 2,021,403 | 0 | 0 | ||
XENON PHARMACEUTICALS INC | COM | 98420N105 | 2,465 | 320,061 | SH | SOLE | 320,061 | 0 | 0 |